Predictors of GON Blockade Success in Migraine

Sponsor
Başakşehir Çam & Sakura City Hospital
Study ID
NCT07170111
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Greater Occipital Nerve (GON) Blockade — PROCEDURE
    The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions

Study Details

This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine. Patients will be evaluated at baseline, on each injection day, and at one- and three-month follow-ups. Study parameters include demographics, migraine type and duration, comorbidities, headache characteristics, treatment history, and validated outcome measures such as the Numeric Rating Scale (NRS), Headache Impact Test-6 (HIT-6), and Global Rating of Change (GRoC). The goal is to establish predictive factors of treatment success in order to optimize patient selection and contribute robust multicenter evidence to individualized migraine management

Key Dates

First listed
Sep 12, 2025
Start date
Sep 15, 2025
Status verified
Aug 2025
Primary completion
Nov 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
460 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GON Block Group

Primary Outcome Measure

Number of days with headache [ Time Frame: Baseline,1st month and 3rd month ]

Central Contacts

Find similar trials

Nationwide
Migraine trialsNeurology trials

Related Studies